For research use only. Not for therapeutic Use.
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy[1][2].
| Catalog Number | I040857 |
| CAS Number | 2578319-11-4 |
| Purity | ≥95% |
| Reference | [1]. Shertel T, et al. Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients. Transplantation. 2022 Oct 1;106(10):e463-e464. [2]. Bebtelovimab. IMGT/mAb-DB. |
